# Open Orphan two new contracts awarded to Venn Life Sciences

- Link: https://www.directorstalkinterviews.com/open-orphan-two-new-contracts-awarded-to-venn-life-sciences/412945747
- Published: 2020-12-07T07:07:13+00:00
- Author: Giles

**Open Orphan plc** ([LON:ORPH](https://www.directorstalkinterviews.com/company/open-orphan-plc/orph.l)),
a rapidly growing specialist CRO pharmaceutical services company which is the world
leader in the testing of vaccines and antivirals using human challenge clinical 
trials has announced its subsidiary Venn Life Sciences has been awarded two new 
contracts.

> **CEO Cathal Friel told DirectorsTalk,** “This RNS announces two very exciting
> deals that our Open Orphan subsidiary Venn Life Sciences has been awarded, from
> both our Paris office and Breda office in the Netherlands. The Paris contract 
> is particularly exciting as it is working on a COVID-19 trial and will likely 
> lead on to substantial more work following this initial contract. Likewise, the
> new contract signed with our Breda team is also a substantial contract and will
> deliver significant new revenues for Venn. These contracts prove that we have 
> successfully integrated Venn and hVIVO into Open Orphan and we now have a very
> exciting, fast growing, profitable CRO on our hands.”

The first contract, which will commence immediately, is a COVID-19 study for a European
pharmaceutical company which involves 200 patients in 50 sites across 5 countries
around the world. Venn’s Paris team will manage the randomisation and supply management
for this randomised, double-blind, placebo-controlled Phase 2 Clinical Trial to 
evaluate the safety and efficacy of a combination treatment of two drugs, and the
best supportive care for patients with moderate and severe COVID-19 in a hospitalised
setting.

Venn’s team based in the Breda office, in the Netherlands has also signed a contract
with a European pharmaceutical company. The contract will see Venn assist with project
management, design and implementation of new processes related to clinical development
and use its expertise to deliver process improvement. The contract, which starts
immediately, will run until December 2021 delivering significant revenues for Venn.

This contract builds on Venn’s existing relationship with this European pharmaceutical
company whom Venn currently provides a variety of services to including IMPD writing,
regulatory briefing book writing, preclinical and clinical consultancy.

> **Cathal Friel, Executive Chairman, Open Orphan, said:**
> “As we come towards the end of 2020, it’s wonderful to see all the elements of
> the Open Orphan business are delivering substantial revenues and both new contract
> wins and renewal of existing long-term customer contracts. The merger and integration
> of Open Orphan, Venn and hVIVO is very much now complete, and having become profitable
> in Q4 2020, we now have a very valuable, fast growing and secure business on our
> hands. Both Venn and hVIVO are converting their substantial pipeline of work whilst
> providing a high-quality service to their customers. The Paris team’s contract
> is a further demonstration of our work in the fight against COVID-19 and the contract
> win by our Dutch Breda team shows how we continue to generate repeat business 
> through our expertise.
> I am very excited by the momentum in the business and look forward to providing
> further updates in the weeks and months ahead of what is going to be a very exciting
> 2021″.

Share on:
